Richard Andrew Newcomb, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Hematopoietic Stem Cell Transplantation | 17 | 2025 | 5717 | 1.760 |
Why?
|
Hematologic Neoplasms | 9 | 2024 | 1907 | 1.360 |
Why?
|
Lymphoma, Non-Hodgkin | 3 | 2024 | 1375 | 0.760 |
Why?
|
Sexual Dysfunction, Physiological | 1 | 2024 | 364 | 0.720 |
Why?
|
Quality of Life | 16 | 2024 | 13490 | 0.660 |
Why?
|
Adaptation, Psychological | 6 | 2024 | 2663 | 0.550 |
Why?
|
Immunotherapy, Adoptive | 3 | 2024 | 1512 | 0.500 |
Why?
|
Lymphoma, B-Cell | 1 | 2021 | 945 | 0.450 |
Why?
|
Graft vs Host Disease | 5 | 2025 | 3049 | 0.400 |
Why?
|
Survivors | 4 | 2024 | 2381 | 0.270 |
Why?
|
Leukemia, Myeloid, Acute | 4 | 2023 | 3626 | 0.260 |
Why?
|
Neoplasms | 7 | 2024 | 22371 | 0.240 |
Why?
|
Fatigue | 3 | 2024 | 1557 | 0.220 |
Why?
|
Bronchiolitis Obliterans | 1 | 2025 | 221 | 0.210 |
Why?
|
Anxiety | 6 | 2024 | 4672 | 0.210 |
Why?
|
Neurotransmitter Agents | 2 | 1998 | 663 | 0.210 |
Why?
|
Cyclophosphamide | 2 | 2024 | 2227 | 0.190 |
Why?
|
Ischemic Attack, Transient | 2 | 1998 | 877 | 0.190 |
Why?
|
Personal Satisfaction | 2 | 2024 | 643 | 0.180 |
Why?
|
Burkitt Lymphoma | 1 | 2023 | 338 | 0.180 |
Why?
|
Reperfusion Injury | 2 | 1998 | 1039 | 0.170 |
Why?
|
Depression | 6 | 2024 | 8230 | 0.170 |
Why?
|
Nitriles | 1 | 2025 | 980 | 0.160 |
Why?
|
Hematologic Diseases | 1 | 2023 | 498 | 0.160 |
Why?
|
Aged | 19 | 2025 | 171504 | 0.160 |
Why?
|
omega-Conotoxins | 1 | 1998 | 17 | 0.150 |
Why?
|
Carcinoma, Large Cell | 1 | 2018 | 114 | 0.150 |
Why?
|
Antigens, CD19 | 1 | 2021 | 446 | 0.150 |
Why?
|
fms-Like Tyrosine Kinase 3 | 1 | 2021 | 494 | 0.150 |
Why?
|
Humans | 40 | 2025 | 768166 | 0.140 |
Why?
|
Middle Aged | 18 | 2025 | 223492 | 0.140 |
Why?
|
Cross-Sectional Studies | 5 | 2024 | 26379 | 0.140 |
Why?
|
Lymphoma, Follicular | 1 | 2021 | 460 | 0.140 |
Why?
|
Bone Marrow Transplantation | 1 | 2024 | 2709 | 0.130 |
Why?
|
Male | 25 | 2025 | 364719 | 0.130 |
Why?
|
Sarcopenia | 1 | 2021 | 378 | 0.130 |
Why?
|
Hospitalization | 8 | 2024 | 10840 | 0.130 |
Why?
|
Bone Marrow | 2 | 2024 | 2935 | 0.120 |
Why?
|
Female | 22 | 2025 | 397192 | 0.120 |
Why?
|
Hospice Care | 1 | 2021 | 678 | 0.120 |
Why?
|
Blood Coagulation | 1 | 2020 | 1162 | 0.120 |
Why?
|
Pyrazoles | 1 | 2025 | 2028 | 0.110 |
Why?
|
Palliative Care | 4 | 2024 | 3643 | 0.110 |
Why?
|
Extracellular Space | 1 | 1996 | 563 | 0.110 |
Why?
|
Potassium | 1 | 1998 | 1315 | 0.110 |
Why?
|
Pilot Projects | 5 | 2024 | 8741 | 0.110 |
Why?
|
Adult | 15 | 2025 | 223646 | 0.100 |
Why?
|
Pyrimidines | 1 | 2025 | 3048 | 0.100 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2023 | 1642 | 0.100 |
Why?
|
Receptors, Antigen, T-Cell | 1 | 2021 | 2568 | 0.100 |
Why?
|
Prognosis | 5 | 2024 | 30010 | 0.100 |
Why?
|
Acute Kidney Injury | 1 | 2023 | 1942 | 0.090 |
Why?
|
Venous Thrombosis | 1 | 2020 | 1323 | 0.090 |
Why?
|
Inpatients | 2 | 2024 | 2566 | 0.090 |
Why?
|
Terminal Care | 1 | 2021 | 1770 | 0.080 |
Why?
|
Amino Acids | 1 | 1996 | 1716 | 0.080 |
Why?
|
Microdialysis | 3 | 2001 | 156 | 0.080 |
Why?
|
Retrospective Studies | 8 | 2024 | 81762 | 0.080 |
Why?
|
Mass Screening | 1 | 2024 | 5458 | 0.070 |
Why?
|
Anemia | 1 | 2017 | 1514 | 0.070 |
Why?
|
Venous Thromboembolism | 1 | 2020 | 1883 | 0.070 |
Why?
|
Pulmonary Embolism | 1 | 2020 | 2599 | 0.070 |
Why?
|
Caregivers | 3 | 2024 | 2302 | 0.070 |
Why?
|
Neoplasm Recurrence, Local | 2 | 2023 | 9419 | 0.070 |
Why?
|
Prospective Studies | 4 | 2025 | 54926 | 0.060 |
Why?
|
Patient Readmission | 1 | 2020 | 3288 | 0.060 |
Why?
|
Muscle, Skeletal | 1 | 2021 | 4978 | 0.060 |
Why?
|
Acute Disease | 2 | 2024 | 7243 | 0.050 |
Why?
|
T-Lymphocytes | 1 | 2021 | 10266 | 0.050 |
Why?
|
Glutamic Acid | 2 | 2001 | 1191 | 0.050 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2018 | 4058 | 0.050 |
Why?
|
Immunotherapy | 1 | 2018 | 4755 | 0.050 |
Why?
|
gamma-Aminobutyric Acid | 2 | 2001 | 1141 | 0.050 |
Why?
|
Bilirubin | 1 | 2023 | 438 | 0.050 |
Why?
|
Renal Replacement Therapy | 1 | 2023 | 282 | 0.050 |
Why?
|
Bone Marrow Examination | 1 | 2021 | 154 | 0.050 |
Why?
|
Cholecystitis | 1 | 2021 | 181 | 0.040 |
Why?
|
Rabbits | 2 | 1998 | 4772 | 0.040 |
Why?
|
Patient Satisfaction | 2 | 2024 | 3488 | 0.040 |
Why?
|
Treatment Outcome | 5 | 2025 | 65371 | 0.040 |
Why?
|
Neurotoxicity Syndromes | 1 | 2024 | 302 | 0.040 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2018 | 5432 | 0.040 |
Why?
|
Self Care | 1 | 2024 | 799 | 0.040 |
Why?
|
Multicenter Studies as Topic | 1 | 2024 | 1737 | 0.040 |
Why?
|
Patient Acceptance of Health Care | 2 | 2023 | 3231 | 0.040 |
Why?
|
Longitudinal Studies | 2 | 2024 | 14783 | 0.030 |
Why?
|
Patients | 1 | 2023 | 908 | 0.030 |
Why?
|
Mutation | 1 | 2021 | 30238 | 0.030 |
Why?
|
Transplantation, Homologous | 1 | 2025 | 4833 | 0.030 |
Why?
|
Taurine | 1 | 1996 | 92 | 0.030 |
Why?
|
Geriatric Assessment | 1 | 2023 | 1422 | 0.030 |
Why?
|
Abdominal Pain | 1 | 2021 | 1070 | 0.030 |
Why?
|
Tissue Donors | 1 | 2024 | 2381 | 0.030 |
Why?
|
Body Temperature | 1 | 1998 | 780 | 0.030 |
Why?
|
Age Factors | 2 | 2024 | 18412 | 0.030 |
Why?
|
Calcium Channel Blockers | 1 | 1998 | 687 | 0.030 |
Why?
|
Chromatography, High Pressure Liquid | 1 | 1998 | 1534 | 0.030 |
Why?
|
Lung Neoplasms | 1 | 2018 | 13586 | 0.030 |
Why?
|
Patient Education as Topic | 1 | 2024 | 2337 | 0.030 |
Why?
|
Aspartic Acid | 1 | 1996 | 577 | 0.030 |
Why?
|
Feasibility Studies | 1 | 2024 | 5315 | 0.030 |
Why?
|
Basal Ganglia | 1 | 1996 | 553 | 0.030 |
Why?
|
Cerebrospinal Fluid | 1 | 1996 | 540 | 0.030 |
Why?
|
Social Support | 1 | 2022 | 2193 | 0.020 |
Why?
|
Aged, 80 and over | 3 | 2024 | 59629 | 0.020 |
Why?
|
Medication Adherence | 1 | 2023 | 2187 | 0.020 |
Why?
|
Immunosuppressive Agents | 1 | 2024 | 4206 | 0.020 |
Why?
|
Hemoglobins | 1 | 2017 | 1531 | 0.020 |
Why?
|
Qualitative Research | 1 | 2022 | 3140 | 0.020 |
Why?
|
Critical Illness | 1 | 2023 | 2756 | 0.020 |
Why?
|
Cerebral Cortex | 2 | 1998 | 5812 | 0.020 |
Why?
|
Intensive Care Units | 1 | 2023 | 3800 | 0.020 |
Why?
|
Biopsy | 1 | 2021 | 6793 | 0.020 |
Why?
|
Recurrence | 1 | 2021 | 8509 | 0.020 |
Why?
|
Stress, Psychological | 1 | 2024 | 4530 | 0.020 |
Why?
|
Brain Ischemia | 1 | 2001 | 3007 | 0.020 |
Why?
|
Analysis of Variance | 1 | 1996 | 6229 | 0.020 |
Why?
|
Patient Discharge | 1 | 2020 | 3479 | 0.020 |
Why?
|
Nuclear Proteins | 1 | 2021 | 5804 | 0.020 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2024 | 10399 | 0.020 |
Why?
|
Clinical Trials as Topic | 1 | 2022 | 8054 | 0.020 |
Why?
|
Young Adult | 2 | 2024 | 60066 | 0.020 |
Why?
|
Severity of Illness Index | 1 | 2024 | 15948 | 0.020 |
Why?
|
Regression Analysis | 1 | 1996 | 6340 | 0.020 |
Why?
|
Peptides | 1 | 1998 | 4354 | 0.020 |
Why?
|
Adolescent | 2 | 2024 | 89169 | 0.020 |
Why?
|
Risk Factors | 2 | 2024 | 74944 | 0.020 |
Why?
|
Incidence | 1 | 2023 | 21538 | 0.020 |
Why?
|
Survival Rate | 1 | 2018 | 12840 | 0.010 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2023 | 11878 | 0.010 |
Why?
|
Laser-Doppler Flowmetry | 1 | 2001 | 238 | 0.010 |
Why?
|
Risk Assessment | 1 | 2020 | 24315 | 0.010 |
Why?
|
Blood Flow Velocity | 1 | 2001 | 1375 | 0.010 |
Why?
|
Animals | 3 | 2001 | 169246 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2018 | 39348 | 0.010 |
Why?
|
Brain | 1 | 2001 | 27360 | 0.010 |
Why?
|
Cerebrovascular Circulation | 1 | 2001 | 2725 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2001 | 22379 | 0.000 |
Why?
|
Disease Models, Animal | 1 | 2001 | 18349 | 0.000 |
Why?
|
Time Factors | 1 | 2001 | 40218 | 0.000 |
Why?
|
Mice | 1 | 2001 | 82029 | 0.000 |
Why?
|